icometrix

icometrix has developed and commercialized FDA-cleared and CE-marked AI solutions for quantitative analysis of brain MRI/CT scans. Their flagship product, icobrain, supports radiologists and neurologists in diagnosing and managing neurological disorders such as multiple sclerosis, Alzheimer’s disease, stroke, traumatic brain injury, epilepsy, dementia, ARIA in Alzheimer's patients on anti–amyloid therapy. The company has published over 250 scientific articles validating its technology. Its products are used by more than 500 clinical practices worldwide; it also partners with pharmaceutical companies to support phase I–III trials and real-world evidence studies through imaging/data services. In the US market it was first to receive AMA reimbursement approval for an AI neuroradiology solution.